Current State of Alzheimer's Disease Research and Therapeutics

Contributors

Hsp90 Modulation for the Treatment of Alzheimer’s Disease

I Introduction

II Hsp90 Complexes in Alzheimer’s Disease

III Potential Therapeutic Effects of Hsp90 Inhibitors in Alzheimer’s Disease

IV Conclusion

Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta

I Introduction

II Rationale for Studying Amyloid Deposition

III General Properties of the Aβ Imaging Tracer, PiB

IV Early Human PiB Studies

V Amyloid Imaging and Apolipoprotein-E Genotype

VI Amyloid Imaging in Normal Controls

VII Amyloid Imaging in MCI

VIII Amyloid Deposition in Early-Onset, Autosomal Dominant, Familial AD

IX Frontotemporal Dementia

X Dementia with Lewy Bodies and Parkinson’s Disease

XI Cerebral Amyloid Angiopathy (CAA)

XII Atypical Presentations of AD

XIII Postmortem Validation of PiB-PET Imaging

XIV Amyloid Imaging Compared to Other Biomarkers

XV Amyloid Imaging in AD Drug Development

XVI F-18 Compounds

XVII Detection of the Earliest Signs of Amyloid Deposition

XVIII Limitations, Validity, and Unresolved Questions

XIX Conclusion

List of Abbreviations

Mitochondrial Abnormalities in Alzheimer’s Disease

I Introduction

II Mitochondrial Function in AD

III Mitochondria as a Therapeutic Target in AD

IV Conclusion

Abbreviations

γ-Secretase as a Target for Alzheimer’s Disease

I Introduction

II γ-Secretase in Alzheimer’s Disease

III γ-Secretase in Biology

IV Biochemistry of the γ-Secretase Complex

V Inhibitors

VI Modulators

VII Conclusion

Abbreviations

Altering Mitochondrial Dysfunction as an Approach to Treating Alzheimer’s Disease

I Introduction

II Theories of Pathogenesis and the Natural History of Alzheimer’s Disease

III Other Pathologies Can Affect Mitochondrial Function

IV Mitochondrial Function Can Exacerbate Other Pathology

V Therapeutic Approaches Being Taken and Opportunities Suggested

VI Conclusion

Abbreviations

scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer’s Disease

I Introduction

II Preclinical Development of scyllo-Inositol

III Sources of scyllo-Inositol

IV Bioavailability and Metabolism

V Human Clinical Trials of scyllo-Inositol as an AD Therapeutic

VI Structure–Function Analysis of scyllo-Inositol

VII Inositol for the Treatment of Other Disorders

VIII Conclusion

Abbreviations

Beyond Amyloid

I Introduction

II Current Therapeutic Targets

III Conclusion

Abbreviations

Activation of Protein Kinase C Isozymes for the Treatment of Dementias

I Introduction

II PKC Signaling System

III Memory and Alzheimer’s Dementia

IV Ischemic Dementia

V Conclusion

Abbreviations

Striatal-Enriched Protein Tyrosine Phosphatase in Alzheimer’s Disease

I Introduction

II Striatal-Enriched Protein Tyrosine Phosphatase (STEP)

III STEP Inhibitors

IV Conclusion

Abbreviations

Estrogen Regulation of Mitochondrial Bioenergetics

I Introduction: Alzheimer’s Disease—Unlimited Cost/Limited Windows of Therapeutic Opportunity

II Role of Mitochondrial Bioenergetics in Alzheimer’s Pathogenesis

III Estrogen Action in the Brain-Convergence upon Mitochondrial Bioenergetics and Brain Metabolism

IV Healthy Cell Bias of Estrogen Action: Consolidation of Clinical Observations and Basic Mechanistic Discoveries

V Clinical Implications for Biomarker Identification and Therapeutic Development for Alzheimer’s Disease

VI Conclusion

Abbreviations

Index

Recent Volumes in the Serial